$ News

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

GENFIT Announces 2026 Financial Calendar

GENFIT: Favorable Phase 1 Safety Profile and Strong Anti-Inflammatory Activity for ACLF Lead Asset G1090N

GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy

Acute on Chronic Liver Failure Market Set to Grow by 2034 as Novel Therapeutic Approaches Enter Clinical Pipeline | DelveInsight

GENFIT Announces Appointment of new Chief Medical Officer

European Equities Traded in the US as ADRs Fall in Friday Trading

Kepler Capital Maintained a Buy Rating on Genfit (GNFT)

Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

GENFIT: June 17, 2025 Combined Shareholders Meeting Results

GENFIT Reports First Quarter 2025 Financial Information

GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen’s Iqirvo® in Italy

GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)

Genfit: Iqirvo's Success Can't Outweigh ACLF Pipeline Risks

GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory Documents

GENFIT to Present Latest ACLF Research at EASL Congress 2025

GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F

GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025

GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update

GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders